AxCell Labs
- Medical device or technology
AxCell Labs is a biotechnology company developing a next-generation soft tissue implant made from bacterial cellulose. Our proprietary material is non-pyrogenic, highly biocompatible, and biointegrative—addressing the limitations of traditional protein-based implants that often trigger immune responses. Designed to serve as a scaffold for tissue regeneration, our implant is being developed for applications such as acellular dermal matrices, aesthetic and dental injectables, and ENT or post-trauma reconstruction. Early in vivo studies show superior biocompatibility and vascularization. Backed by a provisional patent and having just closed a first pre-seed funding, we are now advancing toward functionality tests and ISO 10993 biocompatibility studies in preparation for first-in-human trials by 2027. AxCell is actively seeking strategic partners, collaborators and investors to unlock the full potential of this versatile biomaterial platform.